CIIE Live: AI Reshapes the Health Ecosystem
```
On November 5th, the 8th China International Import Expo officially opened, becoming an important window to observe industrial innovation achievements of companies in the big health sector.
From on-site contract signings and product displays at the Expo to source innovation in drug R&D and the inclusive rollout of terminal health services, AI is reshaping the health industry ecosystem with full-chain penetration and multi-scenario integration.
According to sources, organoid company Yaosu Technology signed a drug R&D cooperation agreement with Medicilon at the event; JD Health's intelligent agent matrix has made health services more accessible; Yingkang Yisheng's future hospital solutions have enabled more precise diagnosis and treatment; Bloomage Biotech's "AI+ECM" research has made anti-aging more scientific.
These practices jointly prove that AI is no longer a "supporting tool" for the health industry, but rather the "core engine" driving industrial upgrading.
As a "connector" for global technology, the China International Import Expo is accelerating the transformation of these AI innovation achievements from exhibits to commodities, and from single breakthroughs to ecosystem-wide collaboration.
With the continuous iteration and implementation of technology, the future health ecosystem will become more efficient, precise, and inclusive, allowing everyone to enjoy the health dividends brought by technological progress.
This revolution, in which AI is reconstructing the health ecosystem, has only just begun.
Solving Innovation Efficiency Pain Points
AI is reshaping the innovation paradigm of the health industry from the source. Whether it's reducing costs and increasing efficiency in drug R&D or making scientific breakthroughs in the anti-aging field, all are inseparable from deep integration with technology and AI.
On November 6th, "AI + Organ-on-a-Chip" company Yaosu Technology reached a strategic partnership with CRO company Medicilon at the Import Expo, becoming a typical case of innovation at the R&D end.
This cooperation will integrate Yaosu Technology’s cutting-edge technology in the organ-on-a-chip field with Medicilon’s internationally standardized large-scale R&D service system to jointly build a new generation of drug R&D platforms with greater predictability and efficiency.
Specifically, Yaosu Technology and Medicilon will collaborate across three main areas: co-developing an organ-on-a-chip R&D and service platform, integrating organ-on-a-chip DMPK pharmacokinetics prediction technology, and pharmacological efficacy + organ-on-a-chip AI integrated solutions.
According to Yaosu Technology, further collaborations with diagnostics and biochip companies are planned to further promote the application of organ-on-a-chip technology.
The collaboration between “AI + organ-on-a-chip” companies and CROs precisely solves the efficiency pain points of traditional drug R&D, and is expected to bring more innovation to the R&D end.
This also aligns with current policy directions.
In April this year, the Ministry of Industry and Information Technology and six other departments issued the “Implementation Plan for the Digital and Intelligent Transformation of the Pharmaceutical Industry (2025–2030),” extracting 41 exemplary scenarios related to technological innovation and development to provide references for pharmaceutical enterprises’ digital transformation.
This includes “animal model data mining and virtual animal experiments”—for high demand for animal alternatives and inconsistency with human results, data mining and simulation technology can be used to establish animal modeling computer simulation models.
In the frontier field of anti-aging, Bloomage Biotech is advancing ECM (extracellular matrix) research through a “30-billion-molecule database + AI R&D platform.”
As one of the few companies worldwide with a systematic approach to key ECM substances, Bloomage Biotech uses AI technology to achieve research from molecules to systems, promoting the anti-aging concept from single substances to system structures.
With ECM changes listed as the 13th hallmark of aging by Cell in 2025, Bloomage Biotech’s AI-driven R&D system is expected to bring more possibilities to anti-aging products.
According to sources from Bloomage Biotech, the company is planning to build regional centers in Europe to achieve "near-shore manufacturing" for rapid response to global market demand.
In the future, with the continued deepening and implementation of such innovative collaborations, AI is expected to further break R&D boundaries, improve efficiency of innovation transformation, bring more disruptive breakthroughs to the health industry, accelerate industry innovation and transformation, and inject lasting momentum into high-quality development in the global health sector.
AI + Full Scenario Coverage
If the R&D end is about AI's deep innovation, the service end is about the broad implementation— from accessible online services to precise in-hospital diagnosis and treatment, AI is making health services more accessible and efficient.
The intelligent service matrix displayed by JD Health at the Expo is quite representative.
According to reports, JD Health relies on its “Jingyi Qianxun” large model to create more than 10 types of professional service intelligent agents, including AI doctors, AI pharmacists, and AI nutritionists, as well as over 1,000 tertiary hospital expert doctor agents, providing 24/7 online triage, consultation, and report interpretation services.
As further introduced by JD Health, the “Jingyi Qianxun” large model can strictly simulate the clinical diagnosis and treatment thinking processes of doctors, deeply integrate medical knowledge systems with real diagnostic logic, and actively introduce and align external evidence-based medical evidence during reasoning to ensure that outputs comply with medical consensus, helping doctors make more precise judgments on complex diseases.
The smart service matrix demonstrated by JD Health at the Expo is a microcosm of integrating cutting-edge AI technologies deeply into the full chain of medical and health services, which is expected to further promote medical services toward greater intelligence and inclusivity.
In in-hospital scenarios, Yingkang Yisheng’s “AI + Healthcare” solution is reshaping the entire diagnostic and treatment process.
Yingkang Yisheng focuses on core scenarios such as “AI + health services,” “AI + oncology diagnosis and treatment,” and “AI + intelligent medication,” launching innovative products such as intelligent consultation, digital mammography machines, and oncology dispensing robots.
Take the scenario of “AI + oncology diagnosis and treatment” as an example: Yingkang Yisheng’s AI-based full-cycle tumor management system integrates data from early screening, diagnosis, treatment to rehabilitation, providing patients with comprehensive personalized solutions including nutrition support and pain management, and promoting a patient-centered approach in oncology care.
With the deep integration of technology and scenarios, AI is expected to continue to empower the industry, enabling leapfrogging improvements in the accessibility, precision, and safety of medical services.
Risk Warning and DisclaimerThe market has risks and investment needs to be cautious. This article does not constitute individual investment advice, nor does it take into account the special investment objectives, financial situation, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article are suitable for their particular situation. Investments based on this are at your own risk. ```